Evidence map›Paper›PMID 22215028›Full record

ArticleOrganic & biomolecular chemistry2012

1-(Fluoroalkylidene)-1,1-bisphosphonic acids are potent and selective inhibitors of the enzymatic activity of Toxoplasma gondii farnesyl pyrophosphate synthase.

Sergio H Szajnman, Valeria S Rosso, Leena Malayil, Alyssa Smith, Silvia N J Moreno, Roberto Docampo, Juan B Rodriguez

Abstract read
In one paragraph

Article in Organic & biomolecular chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sergio H SzajnmanDepartamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA, Buenos Aires, Argentina.
Valeria S Rosso
Leena Malayil
Alyssa Smith
Silvia N J Moreno
Roberto Docampo
Juan B Rodriguez
University of Georgia · USFundación Ciencias Exactas y Naturales · ARUniversity of Buenos Aires · AR

Funding

Drug Discovery Consortium for Chagas DiseaseR01AI082542 · NIAID · UNIVERSITY OF GEORGIA · PI TARLETON, RICK L · 2009 to 2010
$2.2M
The isoprenoid pathway from Toxoplasma gondiiR21AI068467 · NIAID · UNIVERSITY OF GEORGIA · PI MORENO, SILVIA N · 2006 to 2007
$400k
NIAID NIH HHS AI-068467NIAID NIH HHS AI-082542NIAID NIH HHS R01 AI082542NIAID NIH HHS R21 AI068467
6 · The paper itself

Abstract

α-Fluorinated-1,1-bisphosphonic acids derived from fatty acids were designed, synthesized and biologically evaluated against Trypanosoma cruzi, the etiologic agent of Chagas disease, and against Toxoplasma gondii, the agent responsible for toxoplasmosis, and also towards the target parasitic enzymes farnesyl pyrophosphate synthase of T. cruzi (TcFPPS) and T. gondii (TgFPPS). Interestingly, 1-fluorononylidene-1,1-bisphosphonic acid (compound 43) proved to be an extremely potent inhibitor of the enzymatic activity of TgFPPS at the low nanomolar range, exhibiting an IC(50) of 30 nM. This compound was two-fold more potent than risedronate (IC(50) = 74 nM) that was taken as a positive control. This enzymatic activity was associated with a strong cell growth inhibition against tachyzoites of T. gondii, with an IC(50) value of 2.7 μM.

Indexed as

Antiprotozoal AgentsDiphosphonatesEnzyme InhibitorsGeranyltranstransferaseToxoplasma1-fluorononylidene-1,1-bisphosphonic acidAntiprotozoal AgentsDiphosphonatesEnzyme InhibitorsGeranyltranstransferase

Identifiers

PMID22215028
PMCPMC3458512
OpenAlexW2074709062

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.